Drug:
Reaction: PRODUCT USE ISSUE
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25138981 |
CA |
68 | 2 |
Illness, Intra-abdominal fluid collection, Blood pressure increased, Decreased appetite, Nasopharyngitis, Aspartate aminotransferase abnormal, Blood alkaline phosphatase abnormal, Abdominal discomfort, Pruritus, Product dose omission issue, Product use issue, |
||||
OBETICHOLIC ACID, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE, METOPROLOL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, VITAMIN C, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, |
||||
| 2 | 25139444 |
US |
||
Chronic kidney disease, Cardiac disorder, Product use issue, |
||||
TICAGRELOR, DAPAGLIFLOZIN, |
||||
| 3 | 25139752 |
US |
2 | |
Urinary tract infection, Product use issue, |
||||
LEUPROLIDE ACETATE, |
||||
| 4 | 25139767 |
US |
2 | |
Product use issue, Ocular discomfort, Off label use, Cytomegalovirus infection, |
||||
MARIBAVIR, MARIBAVIR, |
||||
| 5 | 25139837 |
US |
8 | 2 |
General anaesthesia, Device issue, Complication of device removal, Complication associated with device, Device breakage, Product use issue, Incorrect product administration duration, |
||||
ETONOGESTREL, |
||||
| 6 | 25139912 |
US |
52 | 2 |
Inability to afford medication, Product use issue, Drug ineffective, |
||||
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, LISDEXAMFETAMINE DIMESYLATE, THYROID, PORCINE, |
||||
| 7 | 25139964 |
US |
70 | 1 |
Product use issue, Product availability issue, |
||||
LENALIDOMIDE, |
||||
| 8 | 25140082 |
BE |
36 | 1 |
Allodynia, Skin burning sensation, Pain of skin, Product use issue, |
||||
GABAPENTIN, FOSFOMYCIN TROMETHAMINE, GRANULES FOR ORAL SOLUTION, |
||||
| 9 | 25140568 |
US |
||
Oral surgery, Product use issue, |
||||
TOLVAPTAN, |
||||
| 10 | 25140745 |
CA |
31 | 2 |
Brain fog, Crohn^s disease, Eye discharge, Fatigue, Rash, Rash pruritic, Therapeutic response shortened, Vision blurred, Product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, COLESTIPOL HYDROCHLORIDE, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, |
||||
| 11 | 25141050 |
CA |
47 | 2 |
Cardiac failure congestive, Drug hypersensitivity, Nausea, Malaise, Drug ineffective, Diarrhoea, Abdominal discomfort, Abdominal pain upper, Arthralgia, Cough, Rash, Headache, Off label use, Product use issue, Hepatic enzyme increased, Liver disorder, Pain, Cardiac failure, Hypersensitivity, Dyspnoea, Gastrointestinal disorder, Hepatic steatosis, Hypertension, Therapeutic product effect decreased, Contraindicated product administered, |
||||
RABEPRAZOLE SODIUM, RABEPRAZOLE, RANITIDINE, COLCHICINE, PATIROMER, CELECOXIB, CEPHALEXIN, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, LEFLUNOMIDE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, ENALAPRIL, ETANERCEPT, ALENDRONATE SODIUM, HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, LOSARTAN, METHOTREXATE, METHOTREXATE SODIUM, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, MOXIFLOXACIN HYDROCHLORIDE, ABATACEPT, PENICILLIN G, HYDROXYCHLOROQUINE SULFATE, ISONIAZID, TOFACITINIB, RITUXIMAB, ADALIMUMAB, HYDROXYCHLOROQUINE SULFATE, ALENDRONATE SODIUM, CLARITHROMYCIN, HYDROXYCHLOROQUINE SULFATE, LEFLUNOMIDE, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, IRON SUCROSE, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, PERINDOPRIL ERBUMINE, PREDNISONE, ATENOLOL, LEVOTHYROXINE, |
||||
| 12 | 25141769 |
CA |
43 | 2 |
Asthenia, Blood cholesterol increased, Drug ineffective, Exposure during pregnancy, Hypertension, Liver function test increased, Liver injury, Maternal exposure during pregnancy, Memory impairment, Mobility decreased, Muscular weakness, Musculoskeletal stiffness, Nausea, Oedema, Off label use, Pain, Pain in extremity, Pemphigus, Pericarditis, Peripheral swelling, Prescribed overdose, Product use in unapproved indication, Product use issue, Psoriatic arthropathy, Rash, Rheumatic fever, Rheumatoid arthritis, Rheumatoid factor positive, Seronegative arthritis, Sleep disorder, Swelling, Spondylitis, Swollen joint count increased, Synovitis, Systemic lupus erythematosus, Therapeutic product effect decreased, Treatment failure, Type 2 diabetes mellitus, Vomiting, Weight decreased, Wheezing, Wound, Wound infection, |
||||
OXYCODONE HYDROCHLORIDE, OXYCODONE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, APREMILAST, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CALCIUM CARBONATE, CELECOXIB, CELECOXIB, CELECOXIB, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, CORTISONE ACETATE, CORTISONE ACETATE, CORTISONE ACETATE, SECUKINUMAB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ETANERCEPT, ETANERCEPT, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, GOLIMUMAB, GOLIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, ADALIMUMAB-ADAZ, INFLIXIMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, HYDROXYCHLOROQUINE SULFATE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, INFLIXIMAB, RITUXIMAB, RITUXIMAB, GOLIMUMAB, GOLIMUMAB, USTEKINUMAB, USTEKINUMAB, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, AZATHIOPRINE, ERYTHROMYCIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LISINOPRIL, LISINOPRIL, MAGNESIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, QUETIAPINE FUMARATE, QUETIAPINE, RAMIPRIL, RISEDRONATE SODIUM, SULFASALAZINE, |
||||
| 13 | 25141804 |
FR |
1 | |
Hallucination, C-reactive protein increased, Confusional state, Product use issue, |
||||
DAROLUTAMIDE, |
||||
| 14 | 25142318 |
US |
2 | |
Product use issue, |
||||
TESTOSTERONE, TESTOSTERONE, |
||||
| 15 | 25142405 |
US |
18 | 2 |
Hereditary angioedema, Hereditary angioedema, Product use issue, Weight increased, |
||||
| 16 | 25142852 |
US |
1 | |
Urinary tract infection, Psychotic disorder, Product use issue, |
||||
| 17 | 25146380 |
|||
Drug ineffective, Product use issue, Withdrawal syndrome, Feeling drunk, Gait disturbance, |
||||
AMANTADINE, |
||||
| 18 | 25138301 |
US |
65 | 2 |
Mouth ulceration, Product use issue, |
||||
FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, |
||||
| 19 | 25137750 |
US |
77 | 2 |
Product use issue, No adverse event, |
||||
| 20 | 25137845 |
US |
68 | |
Product use issue, Gait disturbance, Dyspnoea, Device use issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 21 | 25137890 |
US |
||
Visual impairment, Exposure to extreme temperature, Drug effect less than expected, Wrong technique in device usage process, Product dose omission issue, Product use issue, |
||||
| 22 | 25132110 |
46 | 2 | |
Gastrooesophageal reflux disease, Drug intolerance, Hypersensitivity, Product use issue, Product dose omission issue, |
||||
SOLRIAMFETOL, SOLRIAMFETOL, |
||||
| 23 | 25132128 |
26 | 2 | |
Therapy partial responder, Product use issue, Therapy interrupted, Product availability issue, |
||||
SOLRIAMFETOL, SOLRIAMFETOL, SOLRIAMFETOL, LEVOTHYROXINE, ESCITALOPRAM, ESCITALOPRAM, |
||||
| 24 | 25132130 |
57 | 1 | |
Dizziness, Product use issue, Therapy interrupted, |
||||
SOLRIAMFETOL, |
||||
| 25 | 25132138 |
71 | 1 | |
Somnolence, Drug ineffective, Product use issue, |
||||
SOLRIAMFETOL, NEBIVOLOL HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUPROPION, GABAPENTIN, |
||||
| 26 | 25132362 |
US |
74 | 1 |
Product use issue, |
||||
APIXABAN, APIXABAN, |
||||
| 27 | 25132520 |
US |
||
Chronic obstructive pulmonary disease, Dyspnoea, Cardiac failure congestive, Asthenia, Product use issue, Device use issue, Incorrect dose administered, Device malfunction, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 28 | 25132542 |
US |
82 | 2 |
Product dose omission issue, Wrong technique in product usage process, Product use issue, |
||||
VELPATASVIR AND SOFOSBUVIR, VELPATASVIR AND SOFOSBUVIR, |
||||
| 29 | 25132579 |
US |
1 | |
Haemorrhage, Product distribution issue, Product use issue, |
||||
| 30 | 25132867 |
2 | ||
Asthenia, Product use issue, Therapy interrupted, |
||||
SOLRIAMFETOL, |
||||
| 31 | 25132947 |
US |
1 | |
Product use issue, Insurance issue, |
||||
| 32 | 25132979 |
US |
2 | |
Heavy menstrual bleeding, Menstruation delayed, Headache, Asthenia, Product use issue, |
||||
ETONOGESTREL, |
||||
| 33 | 25132984 |
US |
69 | 1 |
Surgery, Product use issue, Therapy interrupted, |
||||
TENAPANOR HYDROCHLORIDE, |
||||
| 34 | 25133203 |
JP |
8 | 2 |
Recurrent cancer, Triple negative breast cancer, Product use issue, |
||||
PEMBROLIZUMAB, |
||||
| 35 | 25133567 |
US |
67 | 2 |
Drug ineffective, Product use issue, |
||||
GLATIRAMER ACETATE, |
||||
| 36 | 25133602 |
US |
50 | 2 |
Bladder discomfort, Nasal congestion, Urinary tract infection, Product use issue, |
||||
PLECANATIDE, |
||||
| 37 | 25133616 |
US |
81 | |
Acne, Swelling face, Product use issue, |
||||
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, APIXABAN, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 38 | 25133627 |
CN |
52 | |
Gastrointestinal disorder, Product use issue, |
||||
OSIMERTINIB, |
||||
| 39 | 25133652 |
US |
||
Device malfunction, Device use issue, Product use issue, Decreased activity, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 40 | 25133661 |
73 | 1 | |
Nasopharyngitis, Feeling abnormal, Product use issue, Product dose omission issue, Therapy interrupted, Overdose, |
||||
SOLRIAMFETOL, SOLRIAMFETOL, SOLRIAMFETOL, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, FLUOXETINE HYDROCHLORIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, HYDROCHLOROTHIAZIDE, |
||||
| 41 | 25133670 |
75 | 1 | |
Pain, Lethargy, Withdrawal syndrome, Product use issue, Therapy interrupted, Product distribution issue, |
||||
SOLRIAMFETOL, SOLRIAMFETOL, ARIPIPRAZOLE, MIRTAZAPINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ATORVASTATIN CALCIUM, LISINOPRIL, |
||||
| 42 | 25133938 |
US |
77 | 2 |
Product use issue, |
||||
DUPILUMAB, |
||||
| 43 | 25134095 |
US |
2 | |
Product use issue, Device leakage, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 44 | 25134333 |
GB |
71 | |
Prostatitis, Cardiac failure, Product use issue, Dilated cardiomyopathy, |
||||
DAPAGLIFLOZIN, BISOPROLOL FUMARATE, SPIRONOLACTONE, FUROSEMIDE, IVABRADINE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, SACUBITRIL AND VALSARTAN, LANSOPRAZOLE, AMOXICILLIN, AMOXICILLIN, |
||||
| 45 | 25134627 |
US |
||
Product use issue, Product regimen confusion, |
||||
| 46 | 25134628 |
US |
||
Intermenstrual bleeding, Product use issue, Product quality issue, |
||||
| 47 | 25134630 |
US |
||
Product use issue, Product dose omission in error, Product dose confusion, Product administration error, |
||||
| 48 | 25134675 |
US |
43 | 2 |
Product use issue, |
||||
MAVACAMTEN, |
||||
| 49 | 25134681 |
US |
32 | 2 |
Fatigue, Product use issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, BEROTRALSTAT HYDROCHLORIDE, ALBUTEROL SULFATE, ALBUTEROL, LOTEPREDNOL ETABONATE, AZELASTINE, ICATIBANT ACETATE, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, CETIRIZINE HYDROCHLORIDE, |
||||
| 50 | 25134694 |
US |
90 | 2 |
Squamous cell carcinoma of the vulva, Eye haemorrhage, Ocular hyperaemia, Eye pain, Product use issue, Product use issue, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, LACOSAMIDE, VIBEGRON, |
||||
| 51 | 25134761 |
US |
2 | |
Rash, Product use issue, Pruritus, |
||||
PEMBROLIZUMAB, LENVATINIB, LEVOTHYROXINE SODIUM, ERGOCALCIFEROL, CODEINE PHOSPHATE AND GUAIFENESIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, STANDARDIZED SENNA CONCENTRATE AND DOCUSATE SODIUM, POLYETHYLENE GLYCOL 3350, MONTELUKAST SODIUM, CETIRIZINE HYDROCHLORIDE, FAMOTIDINE, |
||||
| 52 | 25134802 |
US |
||
Pneumonia, Norovirus infection, Upper respiratory tract infection, Product use issue, |
||||
| 53 | 25134819 |
CA |
||
Exposure during pregnancy, Food allergy, Hyperhidrosis, Headache, Hepatic enzyme increased, Hypersensitivity, Hypertension, Immunodeficiency, Infusion related reaction, Joint swelling, Pain, Overdose, Prescribed overdose, Product use issue, Intentional product misuse, Off label use, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, TOCILIZUMAB, ALBUTEROL SULFATE, QUETIAPINE FUMARATE, QUETIAPINE, SENNA LEAF, TOCILIZUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ALBUTEROL SULFATE, ALBUTEROL, FLUTICASONE PROPIONATE, |
||||
| 54 | 25135115 |
US |
20 | 2 |
Nephrotic syndrome, Urinary tract infection, Weight decreased, Exposure during pregnancy, Weight increased, Product dose omission issue, Product use issue, Hereditary angioedema, |
||||
WATER, STERILE WATER, STERILE WATER FOR INJECTION, EPINEPHRINE, ADRENALINUM, C1 ESTERASE INHIBITOR RECOMBINANT, |
||||
| 55 | 25135143 |
US |
66 | |
Illness, Product use issue, |
||||
POMALIDOMIDE, |
||||
| 56 | 25135237 |
US |
||
Retinal artery occlusion, Visual impairment, Product use issue, |
||||
DAPAGLIFLOZIN, |
||||
| 57 | 25135247 |
US |
2 | |
Product use issue, |
||||
APIXABAN, |
||||
| 58 | 25135281 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 59 | 25135342 |
US |
2 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 60 | 25135514 |
US |
||
Illness, Product use issue, |
||||
OLAPARIB, |
||||
| 61 | 25135704 |
IN |
79 | 1 |
Death, Off label use, Product use issue, |
||||
PALBOCICLIB, PALBOCICLIB, |
||||
| 62 | 25135965 |
DK |
||
Chest pain, Inappropriate schedule of product administration, Product use in unapproved indication, Product use issue, Off label use, |
||||
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, RIVAROXABAN, MIRTAZAPINE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, FUROSEMIDE, DISULFIRAM, EZETIMIBE, |
||||
| 63 | 25136000 |
US |
||
Intestinal obstruction, Intestinal perforation, Product use issue, |
||||
OLAPARIB, |
||||
| 64 | 25136020 |
US |
2 | |
Diabetes mellitus, Product use issue, |
||||
TENOFOVIR ALAFENAMIDE, |
||||
| 65 | 25136078 |
US |
52 | 2 |
Pneumonia, Bronchitis, Insurance issue, Product use issue, |
||||
| 66 | 25136084 |
BR |
14 | 1 |
Limb injury, Desmoid tumour, Product use issue, |
||||
SORAFENIB, |
||||
| 67 | 25136237 |
US |
68 | 2 |
Product use issue, Intentional product misuse, Product packaging difficult to open, |
||||
| 68 | 25136245 |
US |
83 | 1 |
Product use issue, |
||||
APIXABAN, APIXABAN, |
||||
| 69 | 25136341 |
US |
92 | |
Product use issue, |
||||
APIXABAN, WARFARIN, |
||||
| 70 | 25136349 |
CH |
||
Blood loss anaemia, Anaemia postoperative, Adrenal insufficiency, Malignant neoplasm progression, Lymphadenopathy mediastinal, Pancreatitis, Hilar lymphadenopathy, Coeliac disease, Ophthalmic herpes zoster, Product use issue, Sarcoid-like reaction, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 71 | 25136474 |
BR |
1 | |
Hepatic cancer, Product use issue, |
||||
SORAFENIB, |
||||
| 72 | 25136569 |
DE |
30 | 1 |
Infusion site rash, Drug intolerance, Product use issue, |
||||
| 73 | 25136640 |
US |
1 | |
Inflammatory bowel disease, Joint swelling, Blood creatinine increased, White blood cell count decreased, Injection site mass, Product dose omission issue, Product use issue, Injection site pain, Injection site erythema, Insomnia, Pruritus, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, INFLIXIMAB-DYYB, |
||||
| 74 | 25136709 |
US |
2 | |
Pneumonia, COVID-19, Haemorrhage, Influenza, Product use issue, |
||||
APIXABAN, METOPROLOL TARTRATE, METOPROLOL, INSULIN GLARGINE, DEXMEDETOMIDINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, LEVETIRACETAM, METHYLPREDNISOLONE SODIUM SUCCINATE, ERGOCALCIFEROL, GUAIFENESIN, LEVOTHYROXINE SODIUM, SPIRONOLACTONE, MAGNESIUM, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, |
||||
| 75 | 25136883 |
US |
1 | |
Drug hypersensitivity, Gait disturbance, Fatigue, Pyrexia, Product use issue, |
||||
PEMBROLIZUMAB, LENVATINIB, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, EVEROLIMUS, EVEROLIMUS TABLETS, VALSARTAN, AMLODIPINE BESYLATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, APIXABAN, LEVETIRACETAM, |
||||
| 76 | 25136948 |
US |
1 | |
Neuropathy peripheral, Therapy partial responder, Product use issue, |
||||
BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DARATUMUMAB, |
||||
| 77 | 25126276 |
US |
1 | |
Stoma creation, Product residue present, Product use issue, |
||||
UPADACITINIB, |
||||
| 78 | 25126278 |
US |
37 | 2 |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 79 | 25126559 |
CA |
||
Amnesia, Adjustment disorder with depressed mood, Anxiety, Asthenia, Blood cholesterol increased, Breast cancer stage II, Decreased appetite, Delirium, Depression, Dislocation of vertebra, Dry mouth, Dyspepsia, Facet joint syndrome, Fibromyalgia, Gait disturbance, General physical health deterioration, Grip strength decreased, Headache, Hypertension, Hypoaesthesia, Ill-defined disorder, Inflammation, Injury, Lip dry, Liver disorder, Liver injury, Lung disorder, Malaise, Memory impairment, Migraine, Muscle spasms, Muscular weakness, Musculoskeletal pain, Night sweats, Obesity, Osteoarthritis, Paraesthesia, Peripheral venous disease, Psoriatic arthropathy, Rheumatic fever, Sciatica, Sleep disorder, Swollen joint count increased, Type 2 diabetes mellitus, Weight decreased, X-ray abnormal, Lupus vulgaris, Wound infection, Medication error, Product use issue, Intentional product use issue, Prescribed overdose, Product use in unapproved indication, Off label use, Intentional product use issue, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TOCILIZUMAB, TOCILIZUMAB, |
||||
| 80 | 25126632 |
US |
70 | 2 |
Rash, Product use issue, Contraindicated product administered, |
||||
NICOTINE, |
||||
| 81 | 25126663 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 82 | 25126669 |
US |
43 | 2 |
Off label use, Product use in unapproved indication, Product use issue, Inability to afford medication, |
||||
DEUTETRABENAZINE, |
||||
| 83 | 25126703 |
US |
1 | |
Sciatica, Hypoaesthesia, Product prescribing issue, Product use issue, Product use in unapproved indication, |
||||
CLOMIPHENE CITRATE, CLOMIPHENE CITRTAE, |
||||
| 84 | 25126929 |
US |
2 | |
Product use issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 85 | 25126937 |
US |
46 | 2 |
Product use issue, |
||||
MAVACAMTEN, |
||||
| 86 | 25127367 |
US |
64 | 2 |
Pain, Product use issue, |
||||
ABATACEPT, |
||||
| 87 | 25127679 |
US |
2 | |
No adverse event, Product use in unapproved indication, Product use issue, Product storage error, |
||||
PRUCALOPRIDE, GABAPENTIN, NIFEDIPINE, |
||||
| 88 | 25127738 |
US |
68 | 2 |
Rash, Inappropriate schedule of product administration, Product use issue, |
||||
FREMANEZUMAB-VFRM, |
||||
| 89 | 25127763 |
US |
47 | 2 |
Product use issue, |
||||
APIXABAN, |
||||
| 90 | 25127876 |
US |
||
Dementia, Product use issue, |
||||
DAPAGLIFLOZIN, |
||||
| 91 | 25128118 |
US |
2 | |
Product temperature excursion issue, Product use issue, Pain, |
||||
ABATACEPT, |
||||
| 92 | 25128155 |
US |
61 | 1 |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 93 | 25128188 |
US |
2 | |
Immunoglobulins decreased, Product use issue, |
||||
| 94 | 25128269 |
CA |
||
Product use issue, Off label use, Subretinal fluid, |
||||
FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, AFLIBERCEPT, BEVACIZUMAB, LEUCOVORIN CALCIUM, RANIBIZUMAB, |
||||
| 95 | 25128274 |
US |
||
Product use issue, Device malfunction, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 96 | 25128281 |
US |
47 | 2 |
Product use issue, Liquid product physical issue, Product quality issue, |
||||
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE, |
||||
| 97 | 25128329 |
US |
||
Needle issue, Product use issue, Incorrect dose administered, Product quality issue, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 98 | 25128338 |
US |
1 | |
Product dose omission issue, Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 99 | 25128469 |
US |
19 | 1 |
Hospitalisation, Hypoxia, Pyrexia, Dyspnoea, Product use issue, |
||||
RIOCIGUAT, RIOCIGUAT, |
||||
| 100 | 25128494 |
US |
||
Product use issue, Device malfunction, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28